KZR Share Price Performance
US$7.29
3.26 (80.89%)
Price US$7.29
Share Pricen/a
Kezar Life Sciences, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
KZR Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Kezar Life Sciences, Inc. Key Details
About KZR
- Founded
- 2015
- Employees
- 9
- CEO
- WebsiteView website
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. As of May 11, 2026, Kezar Life Sciences, Inc. operates as a subsidiary of Aurinia Pharma U.S., Inc.
